Catamerò Francesco, Giovannini Mattia, Barni Simona, Liccioli Giulia, Sarti Lucrezia, Tomei Leonardo, Pessina Benedetta, Valleriani Claudia, Marzi Chiara, Baccini Michela, Peroni Diego, Mori Francesca
Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Department of Health Sciences, University of Florence, Florence, Italy.
Ital J Pediatr. 2025 May 23;51(1):154. doi: 10.1186/s13052-025-01947-3.
House dust mite (HDM) is the most common cause of perennial allergy worldwide, causing allergic rhinitis with or without conjunctivitis (AR/C). HDM-related clinical manifestations can be treated with allergy pharmacotherapy or allergen immunotherapy (AIT) in selected cases. AIT is acknowledged as the only therapeutic approach capable of modifying the course of allergic diseases. SQ HDM-SLIT tablets (Accarizax; Merck & Co, Kenilworth, NJ/ALK-Abellò, Hørsholm, Denmark) ensures a constant potency ratio of major HDM allergens of the Dermatophagoides pteronyssinus (DERM_PT) and Dermatophagoides farinae (DERM_FA) HDM species and has demonstrated beneficial effects on allergic rhinoconjunctivitis outcomes. In Italy, rhinoconjunctivitis affects up to as many as 40% of adolescents, but no studies on HDM AIT quality of life (QoL) regarding this exclusive cohort of patients have been specifically conducted. The aim of this study is to evaluate SQ HDM SLIT tablets' performance in improving QoL in Italian adolescents. To assess the treatment at T0, T1, and T2, we employed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(s)), a standardized self-administered questionnaire designed for Italian patients aged 12 and above. RQLQ(s) median values at T2 and T1 were significantly lower than those at T0 (p-values equal to 0.0018 and 0.0051 for T0 vs. T2 and T0 vs. T1, respectively). Our findings suggest that the QoL of SQ HDM SLIT tablet is highly promising, demonstrating substantial potential in alleviating signs and symptoms. Our data suggest that QoL significantly improved with SQ-HDM SLIT, highlighting the potential importance of introducing this therapy for selected cases.
屋尘螨（HDM）是全球常年性过敏最常见的病因，可引发伴有或不伴有结膜炎的过敏性鼻炎（AR/C）。HDM相关的临床表现可通过过敏药物治疗或在特定情况下采用变应原免疫疗法（AIT）进行治疗。AIT被认为是唯一能够改变过敏性疾病病程的治疗方法。皮下注射HDM舌下含片（Accarizax；默克公司，新泽西州肯尼尔沃思/丹麦霍斯霍尔姆的ALK-阿贝洛公司）可确保来自粉尘螨（DERM_PT）和户尘螨（DERM_FA）这两种HDM的主要HDM变应原具有恒定的效价比，并已证明对过敏性鼻结膜炎的治疗效果有益。在意大利，高达40%的青少年患有鼻结膜炎，但尚未专门针对这一特定患者群体开展关于HDM AIT生活质量（QoL）的研究。本研究的目的是评估皮下注射HDM舌下含片对改善意大利青少年生活质量的效果。为了在T0、T1和T2三个时间点评估治疗效果，我们采用了鼻结膜炎生活质量问卷（RQLQ(s)），这是一份为12岁及以上意大利患者设计的标准化自填问卷。T2和T1时RQLQ(s)的中位数显著低于T0时（T0与T2相比以及T0与T1相比，p值分别等于0.0018和0.0051）。我们的研究结果表明，皮下注射HDM舌下含片对生活质量的改善前景非常乐观，在减轻体征和症状方面具有巨大潜力。我们的数据表明，皮下注射HDM舌下含片可显著改善生活质量，凸显了针对特定病例引入这种疗法的潜在重要性。
